Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun Pharma Acquires Rights to ReNeuron Cell Therapies in $113 Million Deal

publication date: Apr 9, 2019

Shanghai Fosun Pharma in-licensed China rights to two cell therapy programs developed by the UK's ReNeuron Group in a $113 million agreement. Fosun will have rights to develop, manufacture and commercialize ReNeuron's CTX and hRPC cell therapies, both of which are clinical-stage candidates. ReNeuron uses stem cell technologies to develop off-the-shelf stem cell treatments that do not require immunosuppressive drugs. Its CTX cell therapy is aimed at treating the effects of a stroke, and the hRPC cells treat the blindness-causing disease, retinitis pigmentosa. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (AIM: RENE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.